I took a bike ride to see a white house, and ‘The White House’, just 4 miles apart this evening 🚲C&O Canal Trust Digestive Disease Week

Always learn something new from Beatriz Gros 💡

Encouraging to see PIs develop drug targets for rare #IBD variants; TTC7A deficiency The Hospital for Sick Children (SickKids)

A few (non-science) observations from Digestive Disease Week so far; 🔋The energy is back! 🥇DC is my fave DDW city (sorry SD) 🤗 IRL connections are as important as who’s on the podium What else? #DDW24

This will be VERY helpful for sponsors to take to FDA; some have lowered wash-out to 4 weeks with FDA sign-off

First-timers at Digestive Disease Week are feeling like this guy tonight (watch the KOLs crush it overhead..) #DDW2024

Yes, these great physicians and scientists are already planning #CCCongress25 in San Francisco; “People are saying, it’s going to be huge” Crohn's & Colitis Foundation American Gastroenterological Association (AGA)

The Crohn's & Colitis Foundation 2024-2029 #IBD Research Strategy is now online! 👏 to the 100+ clinicians, scientists, patients and staff who contributed; academic.oup.com/ibdjournal/iss…

Restoration of the gut mucosal barrier may be important in #IBD. This study in 🐭 does it via orally-delivered PEGylated bacteria 🧫 nature.com/articles/s4155…

Great paper, cool science; ETS2 promotes macrophage inflammatory pathways in #IBD, may be blocked by JAKi, steroids, MEKi 👏🏻 ⁦James Lee⁩ ⁦The Crick⁩ nature.com/articles/s4158…

Since #IBD macrophages are in the news this week, a reminder that vedolizumab also impacts the inflammatory effects of macrophages gut.bmj.com/content/68/1/25

There's been amazing coverage of our new paper nature nature.com/articles/s4158… but I wanted to put together a walk-through (and make this accessible as possible). It's a bit long so get a cup of tea! The full version is open access so pls do have a read if you are interested...

“ustekinumab demonstrated a positive effect on β-cell preservation in children and adolescents with recently diagnosed T1D” Lessons for #IBD ; earlier immune intervention may delay tissue damage Jean-Frederic Colombel The preclinical phase is the next ‘giant step’ for #IBD community

Antimicrobial antibodies (ASCA) present BEFORE a diagnosis of Crohn’s disease have pro-inflammatory effects on immune cells | Nature Immunology nature.com/articles/s4159…

Very practical advice from #ECCO; “drugs should be considered on merit, not sequenced” Now we need to to get medicines agencies and payers to approve them this way.. U.S. FDA EU Medicines Agency

No new biologic / small molecule has been FDA-approved for kids with #IBD in 10 years (despite peds approval in psoriasis and arthritis)! 🤷🏻 Time for Dr. Robert M. Califf AND PhRMA to correct these disparities ⏳

Interested in preclinical models of #IBD? This collection from ⁦IBDJournal & CC360⁩ includes papers on; SAMP1/YitFc ileitis Cannabinoids Exosomal STING Tofacitinib on Macrophages ⁦Sonia Friedman⁩ #FabioCominelli academic.oup.com/ibdjournal/pag…

IBD physicians from across the country belong to our Qorus network. Together, they devised an Urgent Care Toolkit that has helped reduce ER visits by 22%, and hospitalizations by 21% among high-risk IBD patients. Learn more about Qorus: bit.ly/3FN7vVd

Helpful paper from GEM Project; If your sibling/parent has #Crohndisease, your risk of it (2-10%) can be quantified using biomarkers; 💩calprotectin &💧LMR

We are thrilled to announce the 2024 Sherman Prize Recipients, Millie Long, UNC-Chapel Hill UNC School of Medicine UNC Gastroenterology & Dr Dermot McGovern, IBD at Cedars-Sinai Cedars-Sinai, & the Emerging Leader Prize Recipient, Jordan Axelrad, MD, MPH, NYU Langone Health NYU Grossman School of Medicine. Learn more about the honorees at ShermanPrize.org